Literature DB >> 24321534

Clinical and molecular characteristics of mitochondrial DNA depletion syndrome associated with neonatal cholestasis and liver failure.

Abdulrahman Al-Hussaini1, Eissa Faqeih2, Ayman W El-Hattab2, Majid Alfadhel3, Ali Asery4, Badr Alsaleem4, Eman Bakhsh5, Ashraf Ali6, Ali Alasmari2, Khurram Lone4, Ahmed Nahari4, Wafaa Eyaid3, Mohammed Al Balwi7, Kate Craig8, Anna Butterworth8, Langping He8, Robert W Taylor8.   

Abstract

OBJECTIVE: To determine the frequency of mitochondrial DNA depletion syndrome (MDS) in infants with cholestasis and liver failure and to further clarify the clinical, biochemical, radiologic, histopathologic, and molecular features associated with MDS due to deoxyguanosine kinase (DGUOK) and MPV17 gene mutations. STUDY
DESIGN: We studied 20 infants with suspected hepatocerebral MDS referred to our tertiary care center between 2007 and 2013. Genomic DNA was isolated from blood leukocytes, liver, and/or skeletal muscle samples by standard methods. Mitochondrial DNA copy number relative to nuclear DNA levels was determined in muscle and/or liver DNA using real-time quantitative polymerase chain reaction and compared with age-matched controls. Nuclear candidate genes, including polymerase γ, MPV17, and DGUOK were sequenced using standard analyses.
RESULTS: We identified pathogenic MPV17 and DGUOK mutations in 11 infants (6 females) representing 2.5% of the 450 cases of infantile cholestasis and 22% of the 50 cases of infantile liver failure referred to our center during the study period. All of the 11 patients manifested cholestasis that was followed by a rapidly progressive liver failure and death before 2 years of life. Mitochondrial DNA depletion was demonstrated in liver or muscle for 8 out of the 11 cases where tissue was available. Seven patients had mutations in the MPV17 gene (3 novel mutations), 4 patients had DGUOK mutations (of which 2 were novel mutations).
CONCLUSION: Mutations in the MPV17 and DGUOK genes are present in a significant percentage of infants with liver failure and are associated with poor prognosis.
Copyright © 2014 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24321534     DOI: 10.1016/j.jpeds.2013.10.082

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  10 in total

1.  The GABA transaminase, ABAT, is essential for mitochondrial nucleoside metabolism.

Authors:  Arnaud Besse; Ping Wu; Francesco Bruni; Taraka Donti; Brett H Graham; William J Craigen; Robert McFarland; Paolo Moretti; Seema Lalani; Kenneth L Scott; Robert W Taylor; Penelope E Bonnen
Journal:  Cell Metab       Date:  2015-03-03       Impact factor: 27.287

2.  Canine MPV17 truncation without clinical manifestations.

Authors:  Reetta L Hänninen; Saija Ahonen; Merce Màrquez; Maarit J Myöhänen; Marjo K Hytönen; Hannes Lohi
Journal:  Biol Open       Date:  2015-09-09       Impact factor: 2.422

3.  Deep Sequencing Reveals Novel Genetic Variants in Children with Acute Liver Failure and Tissue Evidence of Impaired Energy Metabolism.

Authors:  C Alexander Valencia; Xinjian Wang; Jin Wang; Anna Peters; Julia R Simmons; Molly C Moran; Abhinav Mathur; Ammar Husami; Yaping Qian; Rachel Sheridan; Kevin E Bove; David Witte; Taosheng Huang; Alexander G Miethke
Journal:  PLoS One       Date:  2016-08-02       Impact factor: 3.240

4.  Incidence of Primary Mitochondrial Disease in Children Younger Than 2 Years Presenting With Acute Liver Failure.

Authors:  Patrick McKiernan; Sarah Ball; Saikat Santra; Katherine Foster; Carl Fratter; Joanna Poulton; Kate Craig; Robert McFarland; Shamima Rahman; Iain Hargreaves; Girish Gupte; Khalid Sharif; Robert W Taylor
Journal:  J Pediatr Gastroenterol Nutr       Date:  2016-12       Impact factor: 2.839

5.  NBAS mutations cause acute liver failure: when acetaminophen is not a culprit.

Authors:  Pier Luigi Calvo; Francesco Tandoi; Tobias B Haak; Andrea Brunati; Michele Pinon; Dominic Dell Olio; Renato Romagnoli; Marco Spada
Journal:  Ital J Pediatr       Date:  2017-09-25       Impact factor: 2.638

6.  Nucleotide pools dictate the identity and frequency of ribonucleotide incorporation in mitochondrial DNA.

Authors:  Anna-Karin Berglund; Clara Navarrete; Martin K M Engqvist; Emily Hoberg; Zsolt Szilagyi; Robert W Taylor; Claes M Gustafsson; Maria Falkenberg; Anders R Clausen
Journal:  PLoS Genet       Date:  2017-02-16       Impact factor: 5.917

Review 7.  Gastrointestinal manifestations of mitochondrial disorders: a systematic review.

Authors:  Josef Finsterer; Marlies Frank
Journal:  Therap Adv Gastroenterol       Date:  2016-10-06       Impact factor: 4.409

8.  A fatal case of mitochondrial DNA depletion syndrome with novel compound heterozygous variants in the deoxyguanosine kinase gene.

Authors:  Weiyuan Fang; Peng Song; Xinbao Xie; Jianshe Wang; Yi Lu; Gang Li; Kuerbanjiang Abuduxikuer
Journal:  Oncotarget       Date:  2017-09-15

9.  Clinical and molecular basis of hepatocerebral mitochondrial DNA depletion syndrome in Japan: evaluation of outcomes after liver transplantation.

Authors:  Masaru Shimura; Naomi Kuranobu; Minako Ogawa-Tominaga; Nana Akiyama; Yohei Sugiyama; Tomohiro Ebihara; Takuya Fushimi; Keiko Ichimoto; Ayako Matsunaga; Tomoko Tsuruoka; Yoshihito Kishita; Shuichiro Umetsu; Ayano Inui; Tomoo Fujisawa; Ken Tanikawa; Reiko Ito; Akinari Fukuda; Jun Murakami; Shunsaku Kaji; Mureo Kasahara; Kazuo Shiraki; Akira Ohtake; Yasushi Okazaki; Kei Murayama
Journal:  Orphanet J Rare Dis       Date:  2020-07-24       Impact factor: 4.123

10.  QIL1 mutation causes MICOS disassembly and early onset fatal mitochondrial encephalopathy with liver disease.

Authors:  Virginia Guarani; Claude Jardel; Dominique Chrétien; Anne Lombès; Paule Bénit; Clémence Labasse; Emmanuelle Lacène; Agnès Bourillon; Apolline Imbard; Jean-François Benoist; Imen Dorboz; Mylène Gilleron; Eric S Goetzman; Pauline Gaignard; Abdelhamid Slama; Monique Elmaleh-Bergès; Norma B Romero; Pierre Rustin; Hélène Ogier de Baulny; Joao A Paulo; J Wade Harper; Manuel Schiff
Journal:  Elife       Date:  2016-09-13       Impact factor: 8.140

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.